Advertisement
U.S. markets closed
  • S&P Futures

    5,080.25
    -0.75 (-0.01%)
     
  • Dow Futures

    38,968.00
    -25.00 (-0.06%)
     
  • Nasdaq Futures

    17,907.25
    -8.00 (-0.04%)
     
  • Russell 2000 Futures

    2,047.80
    +4.40 (+0.22%)
     
  • Crude Oil

    78.39
    -0.15 (-0.19%)
     
  • Gold

    2,044.80
    +2.10 (+0.10%)
     
  • Silver

    22.72
    +0.08 (+0.35%)
     
  • EUR/USD

    1.0838
    -0.0005 (-0.04%)
     
  • 10-Yr Bond

    4.2740
    -0.0410 (-0.95%)
     
  • Vix

    13.84
    +0.41 (+3.05%)
     
  • GBP/USD

    1.2666
    +0.0007 (+0.05%)
     
  • USD/JPY

    149.7970
    -0.8360 (-0.55%)
     
  • Bitcoin USD

    61,426.71
    +4,478.05 (+7.86%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,624.98
    -58.04 (-0.76%)
     
  • Nikkei 225

    38,953.49
    -254.54 (-0.65%)
     

Shockwave Medical to Participate in the Piper Sandler 35th Annual Healthcare Conference

Shockwave Medical, Inc.
Shockwave Medical, Inc.

SANTA CLARA, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in the Piper Sandler 35th Annual Healthcare Conference, which is being held from Tuesday, November 28 to Thursday, November 30, 2023 in New York, NY.

Shockwave management is scheduled for a live fireside chat on Wednesday, November 29, 2023, at 1:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the event on the "Investors" section of the company’s website at: https://ir.shockwavemedical.com.

About Shockwave Medical, Inc.

Shockwave Medical is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Shockwave has also recently acquired the Neovasc Reducer, which is under clinical investigation in the United States and is CE Marked in the European Union and the United Kingdom. By redistributing blood flow within the heart, the Reducer is designed to provide relief to the millions of patients worldwide suffering from refractory angina. Learn more at www.shockwavemedical.com and www.neovasc.com.

Media Contact:
Scott Shadiow
+1.317.432.9210
sshadiow@shockwavemedical.com

Investor Contact:
Debbie Kaster
investors@shockwavemedical.com


Advertisement